flatiron

Support bladder cancer research with Panoramic data

Flatiron’s scaled, longitudinal Panoramic dataset spans disease settings and sub-cohorts of interest, enabling greater flexibility across your bladder cancer research priorities.

This latest evolution in Flatiron’s data offerings supports new research questions across your bladder cancer portfolio with 3x larger cohort sizes, comprehensive biomarker details like ctDNA and PD-L1, and rich real-world outcomes and safety insights.

40k+ patients

Flatiron’s Panoramic data includes more than 40,000 bladder cancer patients across diverse disease settings and sub-cohorts of interest.

3x larger cohorts

Larger cohort sizes enable analyses into treatment- and biomarker-defined populations.

Real-world outcomes at scale

Larger cohort sizes enable analyses into treatment- and biomarker-defined populations.

Case Study

Characterizing the patient journey in bladder cancer from the neoadjuvant through metastatic setting

Including MIBC patients in the Panoramic dataset greatly expands the scope of studies across disease severity.

Opportunity

Recent clinical trial results have reshaped the bladder cancer treatment landscape, particularly for muscle-invasive bladder cancer (MIBC). These developments have introduced new therapeutic options for clinicians, including regimens emerging from recent pivotal trials.

Approach

- Stratify patients with MIBC according to the treatment regimen, including chemotherapy, immunotherapy, and surgical details
- Examine what clinical, demographic, and socioeconomic characteristics are associated with the choice of treatment
- Summarize the risk-adjusted outcomes, such as pathologic complete response (pCR) and real-world response (rwR)

Impact

Panoramic data can clarify how clinicians evaluate additional treatment options and the factors associated with their treatment decisions. By leveraging Panoramic data, your teams can add clarity around what patient characteristics should be considered when selecting a neoadjuvant or adjuvant therapy.

Case Study

Describing biomarker testing rates, treatment patterns, and outcomes for emerging and standard of care biomarkers

Panoramic data offers more than twice the sample size for biomarker-defined subgroups, enabling deeper outcomes analyses.

Opportunity

While historically underutilized in bladder cancer, biomarkers such as HER2, FGFR, PD-L1, and ctDNA are increasingly critical to therapy selection and predicting treatment response.

Approach

- Summarize testing patterns and identify areas where testing rates could improve
- Determine the proportions of patients with HER2+, FGFR+, or PD-L1+ status
- Describe treatment and ctDNA testing patterns in each biomarker-defined cohort
- Examine efficacy and safety outcomes with scaled real-world adverse events (rwAEs) and real-world progression-free survival (rwPFS).

Impact

By leveraging Panoramic data, study teams can identify opportunities to improve patient care through appropriate biomarker testing and inform clinical development strategies based on positivity rates and real-world outcomes across biomarker-defined subgroups.

Learn more about Flatiron's Panoramic data solutions for bladder cancer



Learn more about how Flatiron's panoramic data is powering genitourinary cancer insights in this webinar featuring leading researchers from Cleveland Clinic Taussig Cancer Institute, Huntsman Cancer Institute, University of Utah, and Flatiron Health.

Watch webinar recording →